Tagrisso keeps up the pressure on Rybrevant
Four months after Johnson & Johnson boasted of an overall survival advantage for its Rybrevant/Lazcluze combo versus Tagrisso in first-line EGFR-mutant lung cancer, AstraZeneca has made the same claim for its Tagrisso plus chemo doublet. This was already on the cards, Astra earlier revealing a statistically non-significant 25% reduction in risk of death at 41% maturity with Tagrisso plus chemo versus Tagrisso in the Flaura2 trial. On Monday it said this had hit statistical significance and clinical meaningfulness at final analysis, though it's keeping the numbers back for a medical meeting. Expectations are high based on the PFS in Flaura2, and both J&J's Mariposa study and Astra's Flaura trial suggest that the Tagrisso monotherapy comparator should score around 36-39 months of median OS. Rybrevant/Lazcluze hadn't reached a median when the data were presented at the European Lung Cancer Congress, so it's likely that Flaura2 also won't have done yet. But attention might fall on the fact the Mariposa survival curves crossed over before separating, hinting at an initial detriment for Rybrevant/Lazcluze patients, and if Astra can avoid this in Flaura2 this could be a boon even in the absence of a median OS number.
Can Flaura2 beat this? OS curves in Mariposa
99
